These results suggest that in BCL2‐addicted tumor cells, venetoclax monotherapy inhibits proliferation, but not necessarily when combined with BI‐D1870, which reduces other anti‐apoptotic proteins, such as BCL2L1, in these cells. This evidence concerns the gene BCL2 and neoplasm.